Taiwan-based JHL Biotech and Switzerland-based Selexis have formed a biologic drug development alliance to serve the biopharmaceutical industry.
JHL Biotech and Selexis have signed a non-exclusive strategic agreement to provide seamless services to biopharmaceutical customers from cell line development to cGMP manufacturing of biologic drugs.
Leveraging the strengths of the two companies, the alliance will allow biopharmaceutical customers to quickly go from drug candidate DNA to active pharmaceutical ingredient (API) into clinical development and commercialization.
Selexis will provide the fully-documented, high-producing, and stable SURE CHO-M mammalian clonal cell lines, and JHL Biotech will provide process development and manufacturing that follows current good manufacturing practices (cGMP) at their facilities in Hsinchu, Taiwan and Wuhan, China.
The Wuhan facility will be completed in early 2015.
Both companies have been able to rapidly develop and successfully transfer a biosimilar antibody product in their first joint effort.
Selexis generated the high performance SURE CHO-M cell line, which is currently undergoing JHL Biotech's comprehensive process development. JHL Biotech is manufacturing the biosimilar drug at its Hsinchu facility in Taiwan.
JHL Biotech CEO, co-founder and president Racho Jordanov noted biopharmaceutical companies now can turn to JHL Biotech and Selexis for a reliable, rapid process to get products to market in China and the rest of the world.
"Making world-class biologics more affordable just got easier through the partnership of JHL Biotech and Selexis," Jordanov added.
